Medigene axes staff and refocuses its TCR pipeline
Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
Newsletters and Deep Dive digital magazine
Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Jazz Pharma has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
Editor's Picks
Newsletters and Deep Dive
digital magazine